Skip to main content
. 2020 Aug 10;9(Suppl 1):17–30. doi: 10.1159/000508789

Fig. 1.

Fig. 1

Sites of action of novel treatments for GH. CD40L, CD40 ligand; GH, Graves' hyperthyroidism; MAb, monoclonal antibody; MHC Class II, major histocompatibility complex class II molecule; TSH-R, thyrotropin receptor; TSI, thyroid-stimulating immunoglobulin.